| Extended follow-up reveals that first-line melphalan/prednisone plus thalidomide does not provide a survival advantage over melphalan/prednisone alone in patients ≥ 65 years with multiple myeloma. | | June 27, 2008, 3:40 PM | Blood | PubMed |
|
| Clofarabine and low-dose cytarabine therapy demonstrated improved response rates and event-free survival compared to single-agent clofarabine in older patients with AML and high-risk MDS. | | June 25, 2008, 3:03 PM | Blood | PubMed |
|
| Darbepoetin alfa raised hemoglobin levels and was well-tolerated in a phase II trial in patients with low-risk MDS. | | June 25, 2008, 3:02 PM | Br J Haematol | PubMed |
|
| Mutational analysis as a prognostic tool in cytogenetically normal acute myeloid leukemia | | May 8, 2008, 8:29 AM | N Engl J Med | PubMed |
|
| microRNA analysis for prognosis in cytogenetically normal acute myeloid leukemia | | May 8, 2008, 8:29 AM | N Engl J Med | PubMed |
|
| Results from a phase III trial of darbepoetin alfa demonstrate shorter survival and no significant reduction in transfusion occurrence in patients with cancer-related anemia who were not receiving chemotherapy or radiotherapy. | | April 17, 2008, 3:38 PM | J Clin Oncol | PubMed |
|
| High response rates and long-term overall survival were observed in patients with untreated chronic lymphocytic leukemia receiving fludarabine, cyclophosphamide, and rituximab. | | April 17, 2008, 3:37 PM | Blood | PubMed |
|
| An IRIS study subanalysis demonstrated correlation between high imatinib plasma concentrations and good clinical outcomes | | April 16, 2008, 4:09 PM | Blood | PubMed |
|
| Intensive high-dose rituximab-based sequential therapy (R-HDS) as first-line therapy provides superior complete remission rates and event-free survival but not overall survival compared to conventional CHOP-R regimen in patients with high-risk follicular lymphoma | | April 16, 2008, 4:08 PM | Blood | PubMed |
|
| Complete and partial responses are observed in patients with relapsed/refractory CLL treated with lenalidomide, including those with high-risk and fludarabine-refractory disease. | | April 4, 2008, 10:52 AM | Blood | PubMed |
|
|
